Sufferers with HER2-positive superior or metastatic breast most cancers who acquired fam-trastuzumab deruxtecan (Enhertu) plus pertuzumab (Perjeta) reported higher quality-of-life and fewer gastrointestinal, pores and skin, and mucosal unwanted side effects than these receiving the standard-of-care, in response to patient-reported knowledge from the part 3 DESTINY-Breast09 trial.
Knowledge have been offered on the 2025 San Antonio Breast Most cancers Symposium by Dr. Mothaffar F. Rimawi, Dan L. Duncan Complete Most cancers Heart and Baylor School of Medication, Houston, Texas.
The DESTINY-Breast09 trial in contrast Enhertu plus Perjeta to the standard-of-care routine of trastuzumab (Herceptin), Perjeta, and taxane as first-line remedy for sufferers with HER2-positive superior or metastatic breast most cancers. Earlier outcomes present that Enhertu plus Perjeta improved progression-free survival.
In September 2025, the FDA granted precedence evaluate to the supplemental biologics license software of Enhertu for first-line remedy of sufferers with unresectable or metastatic HER2-positive breast most cancers.
In whole, 383 sufferers acquired 5.4 mg/kg of Enhertu as soon as each 3 weeks plus an 840 mg loading dose of Perjeta adopted by 420 mg as soon as each 3 weeks. Within the trastuzumab, Perjeta, and taxane arm, 387 sufferers acquired the standard-of-care mixture of the three medicine.
Affected person-Reported Outcomes Spotlight Variations in Aspect Results
In contrast with trastuzumab, Perjeta, and taxane, Enhertu plus Perjeta presents a definite quality-of-life profile. Sufferers receiving Enhertu plus Perjeta skilled extra gastrointestinal unwanted side effects, together with nausea, vomiting, constipation, and urge for food loss. This group additionally skilled fewer points with pores and skin and mucosal unwanted side effects, nosebleeds, and extremity swelling.
Sufferers in each arms reported related ranges of ache management, fatigue, and general remedy tolerability. The vast majority of sufferers on each therapies efficiently maintained or improved bodily perform all through the examine.
The patient-reported finish factors included time to deterioration in ache, proportion of sufferers experiencing deterioration in treatment-related signs, proportion of sufferers with maintained or improved bodily perform, and general facet impact burden as reported by sufferers.
Influence on ache and bodily perform was largely related between the Enhertu plus Perjeta arm and the trastuzumab, Perjeta, and taxane arm. Median time to deterioration in ache was not reached in both remedy arm.
A excessive share of sufferers in each arms maintained or improved bodily perform. At cycle 2, 83% of sufferers within the Enhertu plus Perjeta arm (328 sufferers) maintained or improved bodily perform versus 82% of sufferers within the trastuzumab, Perjeta, and taxane arm (341 sufferers). At cycle 27 (18.7 months), 75% of sufferers within the Enhertu plus Perjeta arm (187 sufferers) maintained or improved bodily perform versus 78% within the trastuzumab, Perjeta, and taxane arm (166 sufferers).
Major variations in affected person expertise emerged in particular unwanted side effects. Sufferers within the Enhertu plus Perjeta arm skilled extra gastrointestinal points, particularly nausea and vomiting (49% versus 30%). Conversely, sufferers on this arm reported much less deterioration in pores and skin and mucosal unwanted side effects, together with nosebleeds and extremity swelling (23% versus 34% at cycle 2; 37% versus 42% at cycle 27). Deterioration in fatigue was comparable between each arms at cycles 2 (41% versus 42%) and 27 (38% versus 36%). General remedy tolerability was related between the regimens.
Key Takeaways for Sufferers and Physicians from DESTINY-Breast09
The patient-reported outcomes from DESTINY-Breast09 present essential context to the first efficacy and security outcomes. The info conclude that Enhertu plus Perjeta affords sturdy ache management and permits upkeep of bodily perform, outcomes akin to the standard-of-care trastuzumab, Perjeta, and taxane routine.
“Sufferers reported Enhertu and [trastuzumab, Perjeta, and taxane] as equally tolerable over time,” Rimawi concluded throughout the presentation. “The danger of clinically significant deterioration was related, though knowledge are nonetheless immature at this interim evaluation.”
References
- “Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for first-line remedy of sufferers with HER2+ superior/metastatic breast most cancers: patient-reported outcomes from the DESTINY-Breast09 examine,” by Dr. Mothaffar F. Rimawi. Presentation RF6-07. San Antonio Breast Most cancers Symposium. Dec. 10, 2025.
- “Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) remedy of sufferers (pts) with HER2-positive (HER2+) superior/metastatic breast most cancers (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 examine,” by Dr. Mothaffar F. Rimawi. Offered on the San Antonio Breast Most cancers Symposium. Dec. 10, 2025.
For extra information on most cancers updates, analysis and schooling, don’t overlook to
